- Home
- ICU vs PPBT Comparison
ICU vs PPBT Comparison
Compare ICU & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICU
- PPBT
- Stock Information
- Founded
- ICU 2018
- PPBT 2010
- Country
- ICU United States
- PPBT Israel
- Employees
- ICU N/A
- PPBT N/A
- Industry
- ICU Biotechnology: Pharmaceutical Preparations
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- ICU Health Care
- PPBT Health Care
- Exchange
- ICU Nasdaq
- PPBT Nasdaq
- Market Cap
- ICU 10.4M
- PPBT 8.7M
- IPO Year
- ICU N/A
- PPBT N/A
- Fundamental
- Price
- ICU $1.75
- PPBT $3.17
- Analyst Decision
- ICU
- PPBT Strong Buy
- Analyst Count
- ICU 0
- PPBT 2
- Target Price
- ICU N/A
- PPBT $126.50
- AVG Volume (30 Days)
- ICU 24.8K
- PPBT 23.2K
- Earning Date
- ICU 04-15-2025
- PPBT 03-07-2025
- Dividend Yield
- ICU N/A
- PPBT N/A
- EPS Growth
- ICU N/A
- PPBT N/A
- EPS
- ICU N/A
- PPBT N/A
- Revenue
- ICU $68,000.00
- PPBT N/A
- Revenue This Year
- ICU N/A
- PPBT N/A
- Revenue Next Year
- ICU $358.72
- PPBT N/A
- P/E Ratio
- ICU N/A
- PPBT N/A
- Revenue Growth
- ICU N/A
- PPBT N/A
- 52 Week Low
- ICU $1.50
- PPBT $2.00
- 52 Week High
- ICU $27.50
- PPBT $20.60
- Technical
- Relative Strength Index (RSI)
- ICU 43.77
- PPBT 44.15
- Support Level
- ICU $1.71
- PPBT $3.01
- Resistance Level
- ICU $1.99
- PPBT $3.48
- Average True Range (ATR)
- ICU 0.23
- PPBT 0.22
- MACD
- ICU -0.00
- PPBT 0.03
- Stochastic Oscillator
- ICU 2.94
- PPBT 52.63
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.